Zacks Investment Research
05 Nov 2026, 14:50 UTC · 3h ago
MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last?
Impact · against what's priced in
The Q3 sales beat for Keytruda and Gardasil is largely a confirmation of existing expectations and does not provide a catalyst for price appreciation. The identified $200 million inventory headwind for Q4 creates a near-term earnings drag, while the long-term growth requirements remain unmet.
- MRK+0.00
Already priced in
- The price assumes
A steady continuation of Keytruda's current revenue
Keytruda's $7.77 billion in Q3 sales and Gardasil's 14% growth align with the steady revenue base the market already assumes for these core franchises.
What MRK's price assumes · Sep 11
